Holdings (36)
Name | Sector | Instrument | Assets |
---|---|---|---|
Sun Pharmaceutical Industries Ltd. | Healthcare | Equity | 13.43% |
Divi's Laboratories Ltd. | Healthcare | Equity | 9.28% |
Lupin Ltd. | Healthcare | Equity | 7.27% |
Cipla Ltd. | Healthcare | Equity | 5.71% |
Apollo Hospitals Enterprise Ltd. | Healthcare | Equity | 5.31% |
Dr. Reddy's Laboratories Ltd. | Healthcare | Equity | 5.19% |
Glaxosmithkline Pharmaceuticals Ltd. | Healthcare | Equity | 3.61% |
Vijaya Diagnostic Centre Ltd. | Healthcare | Equity | 3.53% |
Abbott India Ltd. | Healthcare | Equity | 3.46% |
Medplus Health Services Ltd. | Healthcare | Equity | 3.41% |
Returns and rankings
1Y | 3Y | 5Y | All | |
---|---|---|---|---|
Fund Returns | 16.01% | 19.17% | 23.65% | 17.73% |
Category Average | 16.68% | 17.78% | 22.58% | NA% |
Rank Within Category | 10.00% | 5.00% | 4.00% | NA% |
Expense ratio, exit load and tax
Expense ratio: 0.91%
Inclusive of GST
Exit load
Exit load of 1% if redeemed within 1 month.
Stamp duty
0.005% (from July 1st, 2020)
Tax implication
Returns are taxed at 20%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 12.5% on returns of Rs 1.25 lakh+ in a financial year.
Fund management
Education
Mr. Bhan is an MBA (Finance) and CFA.
Experience
Prior to joining Nippon India Mutual Fund, he has worked with Emkay Share & Stock Broker Pvt. Ltd, Shah & Sequeira Invst. Pvt. Ltd, ICFAI- Securities Research Center Analyst - Equity Research.
Managed Schemes
Nippon India Large Cap Fund Direct Growth
Nippon India Multi Cap Fund Direct Growth
Nippon India Consumption Fund Direct Growth
Nippon India Pharma Fund Direct Growth
Reliance Close Ended Equity Fund Series A Direct Growth
Reliance Close Ended Equity Fund Series B Direct Growth
Reliance Close Ended Equity Fund II Series A Direct Growth
Nippon India India Opportunities Fund Series A Direct Growth